GenoMed, Inc. Seeks Volunteers for New Emphysema Treatment
ST. LOUIS, Jan. 14 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers with emphysema to test its new treatment approach.
GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases, including emphysema. ACE stands for "angiotensin converting enzyme."
Using genomic epidemiology, GenoMed has discovered that patients with emphysema tend to have overactivity of their ACE enzyme. A logical approach is to inhibit ACE, using ACE inhibitors. GenoMed has already been able to prolong a patient's life with terminal emphysema by seven years, suggesting that ACE inhibition may be the first treatment since oxygen to delay the disease.
The research supporting this new treatment was published in the fall, 2002 in Diabetes Technology and Therapeutics.
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease.
To volunteer, please contact GenoMed's Chief Medical Officer, Dr. David Moskowitz, tel. 314-977-0110, fax 928-395-2580, email: dwmoskowitz@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Dr. David Moskowitz, Chief Medical Officer of GenoMed, Inc., 314-977-0110, or fax, 928-395-2580, or dwmoskowitz@genomedics.com/
Web site: genomedics.com
. |
